Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-0269
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-07-19T01:00:04.860563Z
status: published
lens: trace
sector: health
headline: Clinical applications of artificial intelligence in hypertension management: current evidence and future perspectives
dek: Hypertension remains the leading modifiable risk factor for cardiovascular morbidity and mortality worldwide, with persistently inadequate blood pressure control despite guideline-directed therapy. The rapid expansion of digital health data and computational capacity has positioned artificial intelligence (AI) as a promising tool for improving hypertension management through enhanced risk prediction, phenotyping, and individualized care. However, important challenges related to external validation, interpretabil…
gain_title: AI models predicted incident hypertension and cardiovascular risk from EHRs, wearables and multimodal data with AUCs around 0.75 to 0.90, supporting personalized therapy and remote monitoring.
problem_title: Most AI hypertension studies remain retrospective or internally validated, with few demonstrating external validation or gains in hard outcomes like cardiovascular events or mortality, plus barriers of bias, interpretability, and infrastructure.
trace_subject: AI applications for hypertension management and cardiovascular risk prediction
gain_reading: AI models predicted incident hypertension and cardiovascular risk from EHRs, wearables and multimodal data with AUCs around 0.75 to 0.90, supporting personalized therapy and remote monitoring.
gain_evidence: AI-based models demonstrated favorable performance in predicting incident hypertension and cardiovascular risk using electronic health records, wearable technologies, and multimodal clinical datasets
problem_reading: Most AI hypertension studies remain retrospective or internally validated, with few demonstrating external validation or gains in hard outcomes like cardiovascular events or mortality, plus barriers of bias, interpretability, and infrastructure.
problem_evidence: most available evidence remains based on retrospective or internally validated datasets | relatively few studies have demonstrated robust external validation or improvements in hard clinical outcomes such as cardiovascular events or mortality | Major barriers to implementation include data heterogeneity, algorithmic bias, limited interpretability, insufficient external validation
quick_read: A structured narrative review of literature from January 2015 to December 2025 examined AI for hypertension screening, diagnosis, risk stratification, treatment optimization and remote monitoring. It found ML models often outperformed conventional risk scores with AUCs of 0.75 to 0.90 and showed promise for personalized therapy and continuous monitoring.

The clinical significance remains uncertain because most studies were retrospective without robust external validation, and few showed improvements in cardiovascular events or mortality. The authors conclude prospective validation, transparency, equitable implementation and workflow integration are needed before widespread adoption.
limitation: Evidence base is largely retrospective and internally validated, with few externally validated studies and scarce large prospective randomized trials showing hard outcomes.
tag: Automated dual reading
key_points: Review searched PubMed/MEDLINE, Embase, Scopus for Jan 2015 to Dec 2025 studies on AI for screening, diagnosis, risk stratification, treatment optimization, decision support and remote monitoring. | Machine learning approaches frequently outperformed conventional risk prediction models in included studies. | AI-supported systems showed potential for personalized antihypertensive therapy, resistant hypertension identification, and continuous blood pressure monitoring.
rundown: The review synthesized studies using EHRs, wearables and multimodal datasets for screening, diagnosis, risk stratification, treatment optimization and remote monitoring, noting heterogeneity prevented meta-analysis.

Authors flagged implementation barriers including data heterogeneity, algorithmic bias, limited interpretability, infrastructure and cost requirements, regulatory uncertainty, and patient trust and privacy concerns.
sources:
- peer_reviewed | Herz | https://doi.org/10.1007/s00059-026-05389-3 | 2026-07-17
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

14dd4b02244fd89479063de0346a580a0ae53cfc1ecb43f4bb84150c0b34bdac

previous

0000000000000000000000000000000000000000000000000000000000000000